Zions Bancorporation National Association UT Sells 1,464 Shares of Medpace Holdings, Inc. $MEDP

Zions Bancorporation National Association UT decreased its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 49.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,487 shares of the company’s stock after selling 1,464 shares during the quarter. Zions Bancorporation National Association UT’s holdings in Medpace were worth $788,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. AQR Capital Management LLC lifted its position in Medpace by 65.1% during the third quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock valued at $518,170,000 after purchasing an additional 404,226 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in shares of Medpace by 205.8% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock worth $161,523,000 after buying an additional 211,411 shares during the last quarter. Franklin Resources Inc. raised its position in shares of Medpace by 158.6% during the 4th quarter. Franklin Resources Inc. now owns 299,472 shares of the company’s stock valued at $168,198,000 after buying an additional 183,645 shares in the last quarter. Norges Bank purchased a new stake in shares of Medpace during the 4th quarter valued at $102,156,000. Finally, Goldman Sachs Group Inc. raised its position in shares of Medpace by 92.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 347,049 shares of the company’s stock valued at $194,920,000 after buying an additional 166,654 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors.

Medpace Stock Performance

NASDAQ:MEDP opened at $578.50 on Friday. The firm has a market cap of $16.15 billion, a PE ratio of 33.91, a price-to-earnings-growth ratio of 2.60 and a beta of 1.15. Medpace Holdings, Inc. has a fifty-two week low of $373.00 and a fifty-two week high of $677.90. The business has a 50 day moving average price of $536.23 and a 200-day moving average price of $492.35.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. The company had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm’s revenue was up 17.2% compared to the same quarter last year. During the same period in the prior year, the business posted $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Research analysts predict that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Wall Street Analyst Weigh In

MEDP has been the subject of several research reports. Weiss Ratings upgraded shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $535.00 price target on shares of Medpace in a research report on Thursday, July 23rd. Mizuho upped their price objective on Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. TD Cowen upped their price objective on Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a report on Friday, July 24th. Finally, BMO Capital Markets increased their price objective on Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a research report on Friday, July 24th. Three equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $584.18.

Insider Activity

In other news, CEO August J. Troendle sold 17,610 shares of the stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $605.11, for a total transaction of $10,655,987.10. Following the completion of the sale, the chief executive officer directly owned 615,802 shares in the company, valued at approximately $372,627,948.22. This represents a 2.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Susan E. Burwig sold 7,500 shares of the business’s stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $600.00, for a total value of $4,500,000.00. Following the transaction, the vice president owned 62,984 shares in the company, valued at approximately $37,790,400. This represents a 10.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 67,195 shares of company stock worth $37,989,998 over the last ninety days. 20.50% of the stock is owned by insiders.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.